A NEW WAY TO LOOK AT NEUROPROTECTION
FireCyte is a neuroscience-based ophthalmology company developing novel multi-target intravitreal injected proteins that are both anti-inflammatory and neuroprotective for retinal disorders.
The company’s targeted and risk-mitigated neuroscience play leverages innovative research on microglial activation and direct protection of neurons. There is the potential to extend efforts beyond ophthalmology.
FireCyte has designed novel fusion proteins that engage both SORT1 and DCC, two validated neuroscience targets. Multiple leads have been identified that potently bind to both receptors, with meaningful functional effects. This includes modulating microglial behavior, exhibiting anti-inflammatory activity and having a direct neuroprotective effect.
Investors
